Status:
ENROLLING_BY_INVITATION
Effectiveness of AlloWrap® for the Reduction of Inflammation in ACDF Procedures
Lead Sponsor:
AlloSource
Conditions:
Cervical Stenosis
Spondylolisthesis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The primary objective of this study is to obtain evidence of the effectiveness of AlloWrap Amniotic Membrane in the reduction of soft tissue swelling in two-level ACDF procedures.
Detailed Description
AlloWrap® is a dual sided human amniotic membrane, procured from consented human tissue donors who elect to have scheduled cesarean births. A Human Cells, Tissues, and Cellular and Tissue-Based Produc...
Eligibility Criteria
Inclusion
- Be a skeletally mature male or a non-pregnant, non-lactating female ≥18 years of age;
- Radiographically diagnosed with cervical stenosis or cervical disc disorder and/or degeneration, spondylolisthesis and/or cervical radiculopathy resulting from neural element compression as confirmed by MRI, CT, CT myelogram;
- Neurological dysfunction or radicular symptoms by history and physical exam;
- Is scheduled/or will be scheduled to undergo an anterior cervical fusion, requiring internal fixation using an anterior cervical standalone interbody cage system;
- Failed to gain adequate relief from non-operative treatment, including but not limited to medications, physical therapy, chiropractic care, home exercise and/or for at least 6 weeks; or the patient has progressive muscle weakness or atrophy or intractable pain;
- Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol.
Exclusion
- Have a documented medical history or radiographic evidence of osteoporosis or other condition which would negatively impact the bone healing process (e.g. history of Paget's disease, osteomalacia, or other osteodystrophy) or preclude the subject from receiving screw fixation;
- Have had or plans to have an epidural steroid injection or has taken NSAIDs ≤ 7 days prior to surgery;
- Circulatory, cardiac, or pulmonary problems that could cause excessive surgical risk based on the opinion of the Investigator;
- Active malignancy; Nondiscogenic source of symptoms (e.g., tumor, etc.) or undergoing treatment for tumor or boney traumatic injury to the cervical spine or a history of any invasive malignancy (except non-melanoma skin cancer), unless the patient has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
- Acute cervical trauma ≤ 6 months prior to surgery;
- Inflammatory disease of the cervical spine;
- Has a history of substance abuse (recreational drugs, alcohol) that has been treated in the last 6 months before enrollment for alcohol and/or drug abuse in an in-patient substance abuse program;
- Is currently involved in a study of another investigational product for similar purpose or has been in the previous 90 days;
- Active infection at the operative level, or a systemic infection including prior or pending treatment for HIV, Hepatitis B or Hepatitis C;
- Mentally compromised (e.g., being currently treated for a psychiatric disorder, senile dementia, Alzheimer's disease) in a manner that would compromise his or her ability to participate in the clinical study;
- Currently immunologically suppressed or immunocompromised, or a medical condition requiring radiation, chemotherapy or immunosuppression;
- Subjects who, in the opinion of the Investigator, would not be able or willing to comply with the protocol;
- Have a history of any autoimmune disease, such as, systemic lupus erythematosus (SLE), Addison's disease, Crohn's disease, multiple sclerosis or rheumatoid arthritis;
- Has had prior cervical spine surgery;
- Unstable cardiovascular, renal, hepatic, endocrine and/or pulmonary disease, cancer or uncontrolled diabetes;
- Have symptomatic disease requiring fusion of one level or \> 2 levels and/or requiring fusion between levels C2-C4;
- Has cervical deformity secondary to acute or chronic traumatic fracture or neoplasm, including vertebral, facet or posterior element fracture or dislocation;
- Requires a concomitant posterior cervical surgery at the time of the ACDF;
- Has any contraindications for MRI;
- Is a ward of the state, prisoner, or transient.
Key Trial Info
Start Date :
January 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04684901
Start Date
January 18 2021
End Date
December 1 2027
Last Update
November 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spine Institute of San Diego
San Diego, California, United States, 92120